Pradaxa Lawsuits Settle for $650 Million
Boehringer Ingelheim, the pharmaceutical company that manufactures the blood thinner Pradaxa, announced on Wednesday that it has reached a $650 million settlement in nearly 4,000 state and federal cases filed by U.S. consumers.
The drug Pradaxa was intended as a substitution for warfarin, another blood thinner which posed a higher risk of stroke and systemic embolism in patients who suffer from non-valvular atrial fibrillation.
The U.S. Food and Drug Administration issued a Drug Safety Communication about Pradaxa in May 2014 after the release of a Medicare study which revealed that although Pradaxa did pose a lower risk of strokes caused by blood clots, bleeding of the brain, and death than warfarin, it also caused an increased risk of gastrointestinal bleeding.
In announcing the settlement, the company did not admit to any wrongdoing and maintained that doctors and patients were advised by Boehringer Ingelheim about any health risks associated with taking Pradaxa.